We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer’s disease (AD). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.